Payment overview · 2025
General Payments
$1,021.14
59 reported records · 19 companies
Healthcare provider profile · identity verified
Melissa Rae Lamb, APRN,BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · NEWPORT, TN · NPI 1013998038
Verified facts
What the public records show
CMS Open Payments records show Melissa Rae Lamb, APRN,BC received $1,021.14 in general payments during 2025 across 59 reported records.
GlaxoSmithKline, LLC. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $184.20 | 18.0% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $170.50 | 16.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.55 | 13.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.29 | 9.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.74 | 6.4% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $55.35 | 5.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $49.11 | 4.8% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.51 | 4.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.80 | 2.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.39 | 2.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.39 | 2.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.80 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.41 | 2.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.28 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.32 | 1.6% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $16.29 | 1.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.60 | 1.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.15 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.46 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,021.14 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $148.04 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $94.65 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.65 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.71 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $80.76 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $70.79 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $66.51 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $66.51 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $55.35 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $52.15 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.64 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.51 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.92 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.78 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.80 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.22 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 43 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 97 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
123 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
97 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 86 |
| Gabapentin | Gabapentin | 309 | 64 |
| Prednisone | Prednisone | 274 | 184 |
| Lisinopril | Lisinopril | 269 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 68 |
| Omeprazole | Omeprazole | 216 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 59 |
| Furosemide | Furosemide | 192 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 52 |
| Montelukast Sodium | Montelukast Sodium | 166 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 165 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 45 |
| Losartan Potassium | Losartan Potassium | 146 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 43 |
| Potassium Chloride | Potassium Chloride | 140 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 36 |
| Jardiance | Empagliflozin | 123 | 38 |
| Fluconazole | Fluconazole | 122 | 72 |
| Doxycycline Hyclate | Doxycycline Hyclate | 109 | 96 |
| Metformin Hcl | Metformin Hcl | 106 | 31 |
| Metformin Hcl Er | Metformin Hcl | 101 | 30 |
| Mounjaro | Tirzepatide | 97 | 22 |
| Cefdinir | Cefdinir | 94 | 74 |
| Alendronate Sodium | Alendronate Sodium | 91 | 35 |
| Ozempic | Semaglutide | 86 | 28 |
| Carvedilol | Carvedilol | 85 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 20 |
| Pregabalin | Pregabalin | 82 | 19 |
| Buspirone Hcl | Buspirone Hcl | 81 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 22 |
| Famotidine | Famotidine | 79 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 38 |
| Donepezil Hcl | Donepezil Hcl | 66 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 52 |
| Promethazine Hcl | Promethazine Hcl | 59 | 25 |
| Tramadol Hcl | Tramadol Hcl | 59 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 59 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 16 |
| Repatha Sureclick | Evolocumab | 55 | 11 |
| Simvastatin | Simvastatin | 52 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 48 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 17 |
| Meloxicam | Meloxicam | 47 | 16 |
| Spironolactone | Spironolactone | 47 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 22 |
| Eliquis | Apixaban | 43 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 11 |
| Memantine Hcl Er | Memantine Hcl | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 18 |
| Nystatin | Nystatin | 37 | 15 |
| Kerendia | Finerenone | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 32 |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 11 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 13 |
| Linzess | Linaclotide | 32 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 11 |
| Roflumilast | Roflumilast | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 27 |
| Cephalexin | Cephalexin | 26 | 21 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 11 |
| Naproxen | Naproxen | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,021.14 · 59 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAMZYOS, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GEMTESA, GVOKE HYPOPEN, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, bio-ConneKt | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error